Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents

被引:26
|
作者
Salado, Irene G. [1 ]
Zaldivar-Diez, Josefa [1 ]
Sebastian-Perez, Victor [1 ]
Li, Lingling [2 ]
Geiger, Larissa [1 ]
Gonzalez, Silvia [1 ]
Campillo, Nuria E. [1 ]
Gil, Carmen [1 ]
Morales, Aixa V. [2 ]
Perez, Daniel I. [1 ]
Martinez, Ana [1 ]
机构
[1] CSIC, Dept Chem & Phys Biol, Ctr Invest Biol, Madrid, Spain
[2] CSIC, Dept Mol Cellular & Dev Neurobiol, Inst Cajal, Madrid, Spain
关键词
LRRK2; inhibitors; Protein kinase inhibitors; Indolinone; Adult neurogenesis; Neural stem cell; Regenerative medicine; PARKINSONS-DISEASE; EFFICIENT SYNTHESIS; SCHIFF-BASES; STEM-CELLS; BIOLOGY; ISATIN; MUTATIONS;
D O I
10.1016/j.ejmech.2017.06.060
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Leucine-rich repeat kinase 2 (LRRK2) is one of the most pursued targets for Parkinson's disease (PD) therapy. Moreover, it has recently described its role in regulating Wnt signaling and thus, it may be involved in adult neurogenesis. This new hypothesis could give rise to double disease-modifying agents firstly by the benefits of inhibiting LRRK2 and secondly by promoting adult neurogenesis. Herein we report, the design, synthesis, biological evaluation, SAR and potential binding mode of indoline-like LRRK2 inhibitors and their preliminary neurogenic effect in neural precursor cells isolated from adult mice ventricular-subventricular zone. These results open new therapeutic horizons for the use of LRRK2 inhibitors as neuroregenerative agents. Moreover, the indolinone derivatives here prepared, inhibitors of the kinase activity of LRRK2, may be considered as pharmacological probes to study the potential neuroregeneration of the damaged brain. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:328 / 342
页数:15
相关论文
共 50 条
  • [1] Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
    Estrada, Anthony A.
    Sweeney, Zachary K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) : 6733 - 6746
  • [2] Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Greshock, Thomas J.
    Sanders, John M.
    Drolet, Robert E.
    Rajapakse, Hemaka A.
    Chang, Ronald K.
    Kim, Boyoung
    Rada, Vanessa L.
    Tiscia, Heather E.
    Su, Hua
    Lai, Ming-Tain
    Sur, Sylvie M.
    Sanchez, Rosa I.
    Bilodeau, Mark T.
    Renger, John J.
    Kern, Jonathan T.
    McCauley, John A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (11) : 2631 - 2635
  • [3] Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond
    Goering, Stefan
    Taymans, Jean-Marc
    Baekelandt, Veerle
    Schmidt, Boris
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (19) : 4630 - 4637
  • [4] Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization
    Sen, Saurabh
    Webber, Philip J.
    West, Andrew B.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (52) : 36346 - 36356
  • [5] Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis
    Kim, Hyejung
    Son, Ilhong
    Seol, Wongi
    ANIMAL CELLS AND SYSTEMS, 2018, 22 (01) : 15 - 21
  • [6] Screening and structural strategies for the design of selective Leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Chen, Ijen
    David, Laurent
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [7] Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
    Smith, WW
    Pei, Z
    Jiang, HB
    Moore, DJ
    Liang, YD
    West, AB
    Dawson, VL
    Dawson, TM
    Ross, CA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) : 18676 - 18681
  • [8] Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
    Lee, Byoung Dae
    Dawson, Valina L.
    Dawson, Ted M.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (07) : 365 - 373
  • [9] Discovery and evaluation of selective, orally available and brain penetrant inhibitors of leucine rich repeat kinase 2 (LRRK2)
    DeMong, Duane
    Basu, Kallol
    Scott, Jack
    Miller, Michael
    Agnihotri, Gautam
    Baptista, Marco
    Cheewatrakoolpong, Boonlert
    Columbus, John
    Dai, Xing
    Duan, Xiaobang
    Fell, Matthew
    Frank, Emily
    Frassetto, Andrea
    Greshock, Thomas
    Harris, Joel
    Hruza, Alan
    Hu, Zhiyong
    Li, Wei
    Lin, Sue-Ing
    Liu, Hong
    Macala, Megan
    Mei, Hong
    Mirescu, Christian
    Morrow, John
    Poirier, Marc
    Scapin, Giovanna
    Sherborne, Bradley
    Smith, Michelle
    Stevenson, Heather
    Strickland, Corey
    Tempest, Paul
    Vicarel, Monica
    Walsh, Paul
    Xiao, Li
    Zhang, Honglu
    Zhou, Xiaoping
    Duffy, Joseph
    Kennedy, Matthew
    McCauley, John
    Nargund, Ravi
    Parker, Eric
    Ruck, Rebecca
    Stamford, Andrew
    Weber, Ann
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [10] Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson's Disease
    Gilligan, Paul J.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (10) : 927 - 938